Immunocore Holdings plc American Depositary Shares (IMCR) is a publicly traded Healthcare sector company. As of May 21, 2026, IMCR trades at $29.54 with a market cap of $1.44B and a P/E ratio of -54.60. IMCR moved +2.14% today. Year to date, IMCR is -9.80%; over the trailing twelve months it is -8.80%. Its 52-week range spans $23.15 to $40.71. Analyst consensus is buy with an average price target of $62.33. Rallies surfaces IMCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Immunocore Q1 KIMMTRAK Sales Climb 13.6% to $106.7M with $845M Cash: Immunocore posted Q1 net sales of $106.7 million for KIMMTRAK, up 13.6% year-over-year, and ended March 31 with $845 million in cash and securities, while net income rose to $13.0 million ($0.25 per share). Phase 3 data showed KIMMTRAK doubled five-year survival in metastatic uveal melanoma (16% vs 8%; HR0.67).
| Metric | Value |
|---|---|
| Price | $29.54 |
| Market Cap | $1.44B |
| P/E Ratio | -54.60 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.71 |
| 52-Week Low | $23.15 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $412.81M |
| Net Income | $-27.57M |
| Gross Margin | 98.86% |
10 analysts cover IMCR: 0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $62.33.